Table 9.
Recurrence outcomes reported in studies eligible for quantitative synthesis.
| Study | Study Design | Recurrence Descriptors Reported for HR+/HER2- eBC Patients |
|||||
|---|---|---|---|---|---|---|---|
| DFS | DDFS | LR | DR | Any R | Other | ||
| BIG 1-98 | RCT | X | |||||
| TEAM | RCT | X | |||||
| SOFT | RCT | X | |||||
| FACE | RCT | X | |||||
| DATA | RCT | X | |||||
| SOLE | RCT | X | |||||
| GEICAM/2006-10 | RCT | X | X | X | X | TTR | |
| Kurebayashi (2017) NCT01546649 | RCT | X | X | ||||
| Laenkholm (2018) | RWE | X | TTR | ||||
| Kwak (2015) | RWE | X | |||||
| Alramadhan (2016) | RWE | X | X | X | X | ||
| Shimazu (2019) | RWE | X | X | ||||
Abbreviations: R = recurrence; DDFS = distant disease-free survival; DFS = disease-free survival; DR = distant recurrence; eBC = early breast cancer; HER2 = human epidermal growth factor receptor 2; HR = hormone receptor; RCT = randomized controlled trial; RWE = real-world evidence; TTR = time to recurrence.